

FINAL ANNOUNCEMENT
XVTH JOINT LIPIDOLOGISTS' MEETING
MAY 4TH/ 5TH, 2007 IN LUGANO

- Scientific committee:** PD Rubino Mordasini, MD, Berne
Prof. Walter F. Riesen, Dr. h.c., St. Gall
Prof. Arnold von Eckardstein, MD, Zurich
Prof. Giorgio Nosedà, MD, Mendrisio
- Venue / accommodation:** Hotel de la Paix
Viale Giuseppe Cattori 18, CH – 6900 Lugano
- The meeting will be held by the:** Swiss Atherosclerosis Association
German Atherosclerosis Society
New French Atherosclerosis Society

Programme **Friday, May 4th, 2007**

- as of 11:00 a.m. *Welcome drink*
- 11:30 – 12:30 p.m. *Lunch*
- 12:35 – 12:45 p.m. **Welcome address****
Rubino Mordasini, Berne
- 12:45 – 03.15 p.m. **New targets for the treatment of dyslipidemia and prevention of atherosclerosis: part I****
Chairpersons: Rubino Mordasini, Berne / Walter F. Riesen, St. Gall
- 12:45 – 01:15 p.m. Cardiovascular actions of TZDs
B. Staels, Lille (FR)
- 01:15 – 01:30 p.m. Different dose of clopidogrel and platelet resistance
F. Mach, Geneva
- 01:30 – 02:00 p.m. Comparative Atorvastatin Pleiotropic (CAP) effects study
J. Bonnet, Pessac (FR)
- 02:00 – 02:15 p.m. Deciphering the Low Density Lipoprotein-induced p38 MAPK signaling pathway
N. Bulat, Lausanne
- 02:15 – 02:30 p.m. Inadequate control of high blood cholesterol levels in a Swiss population - the CoLaus Study
M. Firmann, Lausanne
- 02:30 – 02:45 p.m. Strength of motivation to reduce major cardiovascular risk factors in a general population
R. Darioli, Lausanne (A. Chiolero, Lausanne)

Scientific committee:
PD Rubino Mordasini, M.D., Berne
Prof. Walter F. Riesen, M.D., Dr. h.c., St. Gall
Prof. Arnold von Eckardstein, M.D., Zurich
Prof. Giorgio Nosedà, M.D., Mendrisio

Sponsors:

Administration:
Dr. Schlegel Healthworld AG
Heidi Fuchs / Sandra Gander
Sennweidstrasse 46, 6312 Steinhausen
Tel. 041 748 76 00 / Fax 041 748 76 11
E-mail: h.fuchs@schlegelhealth.ch

AstraZeneca 


Takeda Pharma

- 02:45 – 03:00 p.m. Adoption of the "Healthy Heart Kit" by primary care physicians in Alberta
R. Bize, Lausanne
- 03:00 – 03:15 p.m. The impact of carotid plaque screening on motivation for smoking cessation and knowledge retention about atherosclerosis
N. Rodondi, Lausanne
- 03:15 – 03:45 p.m. *Break*
- 03:45 – 06:00 p.m.**
New targets for the treatment of dyslipidemia and prevention of atherosclerosis: part II
Chairpersons: *Arnold von Eckardstein, Zurich / Edouard Battegay, Basle*
- 03:45 – 04:15 p.m. HDL: Any new arrows in the quire?
F. Ruschitzka, Zurich
- 04:15 – 04:30 p.m. High Density Lipoprotein-induced [beta] cells protection: a transcriptomic approach to the identification of new therapeutic targets
J. Pétremand, Lausanne
- 04:30 – 04:45 p.m. Liver X Receptor (LXR) agonists induce SR-BI disappearance from apical microvillousities in Caco2-TC7 enterocytes: a way for dietary sterols to modulate intestinal lipids absorption
O. Briand, Lille (FR)
- 04:45 – 05:00 p.m. Primary hypertriglyceridemias are associated with nonalcoholic fatty liver disease (NAFLD)
E. Seelig, Basle
- 05:00 – 05:15 p.m. Role of adipokines in obesity and inflammation
U. Keller, Basle
- 05:15 – 05:30 p.m. The metabolic syndrome and angiographically diagnosed coronary artery disease are additive determinants of serum adiponectin
C. H. Saely, Feldkirch (AT)
- 05:30 – 06:00 p.m. Dipeptidyl peptidase inhibitors: a new step towards normoglycemia
A. Fredenrich, Nice (FR)
- 06:30 p.m. *Start evening programme*

Scientific committee:

PD Rubino Mordasini, M.D., Berne
Prof. Walter F. Riesen, M.D., Dr. h.c., St. Gall
Prof. Arnold von Eckardstein, M.D., Zurich
Prof. Giorgio Nosedà, M.D., Mendrisio

Sponsors:

Administration:

Dr. Schlegel Healthworld AG
Heidi Fuchs / Sandra Gander
Sennweidstrasse 46, 6312 Steinhausen
Tel. 041 748 76 00 / Fax 041 748 76 11
E-mail: h.fuchs@schlegelhealth.ch



Programme

Saturday, May 5th, 2007

08:30 – 10:15 a.m.

From better understanding of atherosclerosis to novel diagnostic markers: part I

Chairpersons:

Giorgio Nosedà, Mendrisio / François Mach, Geneva

08:30 – 09:00 a.m.

Antioxidant enzymes in atherogenesis - towards a better understanding of their role?

K. Lackner, Mainz (DE)

09:00 – 09:15 a.m.

Oxidation of HDL modifies its capacity to influence paraoxonase-1 metabolism

R. James, Geneva

09:15 – 09:30 a.m.

Chronic and acute oxidative stress in the function of the arterial wall

H. Heinle, Tübingen (DE)

09:30 – 09:45 a.m.

Summary of evidence that non-oxidative, enzymatic remodeling is the biologically relevant modification of intimal LDL

S. Bhakdi, Mainz (DE)

09:45 – 10:00 a.m.

Serine-Palmitoyltransferase is a high molecular weight complex – cloning and initial characterisation of a new subunit

T. Hornemann, Zurich

10:00 – 10:30 a.m.

Break

10:30 – 12:00 p.m.

From better understanding of atherosclerosis to novel diagnostic markers: part II

Chairpersons:

Richard James, Geneva / Ulrich Keller, Basle

10:30 – 11:00 a.m.

New biomarkers for the diagnosis and prognosis of cardiovascular disease

A. von Eckardstein, Zurich

11:00 – 11:15 a.m.

Novel diagnostic markers with reference to plaque macrophages

J. Metz, Heidelberg (DE)

11:15 – 11:30 a.m.

Development of cytokine biomarkers for chronic disease

S. Visvikis-Siest, Nancy (FR)

Scientific committee:

PD Rubino Mordasini, M.D., Berne
Prof. Walter F. Riesen, M.D., Dr. h.c., St. Gall
Prof. Arnold von Eckardstein, M.D., Zurich
Prof. Giorgio Nosedà, M.D., Mendrisio

Sponsors:

Administration:

Dr. Schlegel Healthworld AG
Heidi Fuchs / Sandra Gander
Sennweidstrasse 46, 6312 Steinhausen
Tel. 041 748 76 00 / Fax 041 748 76 11
E-mail: h.fuchs@schlegelhealth.ch

AstraZeneca 


Takeda Pharma

- 11:30 – 11:45 a.m. Rabbit CRP transgene expression is more pronounced in male compared to female LDL-R^{-/-} mice and causes accelerated atherosclerosis in male but not female LDL-R^{-/-} mice
M. Torzewski, Mainz (DE)
- 11:45 – 12:00 a.m. Genetic heterogeneity of autosomal dominant hypercholesterolemia
M. Varret, Paris (FR)
- 12:00 – 01:00 p.m. Lunch
- 01:00 – 03:00 p.m.**
Chairpersons:
Rubino Mordasini, Berne / Walter F. Riesen, St. Gall
- 01:00 – 01:30 p.m. TITEL NN
REFERENT ASTRAZENECA
- 01:30 – 01:45 p.m. Relationship between cardiovascular risk factors, atherosclerosis burden and diameter of abdominal aorta: a prospective study
F. Glauser, Lausanne
- 01:45 – 02:00 p.m. The subclinical atherosclerosis burden across AGLA Score among asymptomatic adults in the Lausanne Atherosclerosis Registry
I. Stauffer, Lausanne
- 02:00 – 02:15 p.m. Subclinical atherosclerosis imaging as a new tool to evaluate the appropriateness of guidelines for the primary prevention of cardiovascular disease among young adults
M. Depairon, Lausanne
- 02:15 – 02:30 p.m. Screening of coronary artery disease in diabetic patients
J. Ruiz, Lausanne
- 02:30 – 02:45 p.m. The Taskforce on Vascular Risk Prediction Update 2007
M. Romanens, Olten
- 02:45 – 03:00 p.m. Understanding the estrogen action in experimental and clinical atherosclerosis
J. F. Arnal, Toulouse (FR)
- 03:00 – 03:05 p.m.**
Closing remarks
Rubino Mordasini, Berne

Scientific committee:

PD Rubino Mordasini, M.D., Berne
Prof. Walter F. Riesen, M.D., Dr. h.c., St. Gall
Prof. Arnold von Eckardstein, M.D., Zurich
Prof. Giorgio Nosedà, M.D., Mendrisio

Sponsors:

Administration:

Dr. Schlegel Healthworld AG
Heidi Fuchs / Sandra Gander
Sennweidstrasse 46, 6312 Steinhausen
Tel. 041 748 76 00 / Fax 041 748 76 11
E-mail: h.fuchs@schlegelhealth.ch

AstraZeneca 


Takeda Pharma